Searched for
SYNGENE PROFIT
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Smallcap winners! Wockhardt, Tata Tech, CAMS, other stocks rally up to 11% despite overall market weaknessSmallcap stocks outperformed on Tuesday despite weak broader markets, with Wockhardt, Tata Tech and CAMS gaining up to 11% on strong Q4 ear...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- Syngene Q3 Results: Net profit rose 18% YoY to Rs 131 croreSyngene reported 18% YoY growth in Q3FY25 net profit. Revenue rose 11% YoY. EBITDA margin improved to 31.4%. Company expects single-digit r...
- Syngene International Q4 Results: Net profit jumps 21% to YoY Rs 179 croreHunt said the manufacturing services had a particularly strong year, led by the commercial-scale biologics manufacturing business, which ha...
- Syngene reports Rs 102 crore net profit in Q2FY23The company reported net profit of Rs 102 crore during Q2FY23, compared to Rs 67 crore during the corresponding quarter of the previous yea...
- Syngene International Q1 results: Net profit rises 33% to Rs 77 cr; John Shaw to step down from boardConsolidated revenue from operations of the company stood at Rs 594.5 crore for the quarter under consideration. It was Rs 421.6 crore for ...
- Syngene International Q3 results: Profit rises 11% to Rs 102 crRevenue from the operations stood at Rs 585 crore in the quarter under review. It was Rs 519 crore in December quarter 2019-20, it added.
- Syngene International shares jump 5% after Q4 earningsThe company on Wednesday reported a 20 per cent rise in its consolidated net profit to Rs 120 crore for the quarter ended March 31, 2020, d...
- Syngene International Q4 results: Profit up 20% to Rs 120 croreThe company had posted a net profit of Rs 100 crore for the corresponding period of the previous fiscal.
- Syngene Q1 Net up 28% at Rs 60 croreThe company had posted a net profit of Rs 46.6 crore for the corresponding period of the previous fiscal, Syngene International said in a f...
- Syngene International Q3 net profit up 31% at Rs 59 croreSyngene International has reported a 31.25 per cent rise in its net profit to Rs 58.8 crore for the third quarter ended December 31.
- Syngene Q3 net up 31% to Rs 59 croreBiocon's contract research arm Syngene International reported 31.25% rise in net profit to Rs 58.8 crore for the third quarter of 2015-16 f...
- Syngene Q2 net profit rises 31% to Rs 52 croreSyngene International, research arm of Biocon, today posted 30.69 per cent rise in its net profit at Rs 52.29 crore for the second quarter ...
- Is it time to book profits on Biocon counter post Syngene listing?Biocon has gained nearly 9 per cent in the past six months, compared to a 2 per cent fall in the BSE benchmark Sensex.
- Top five reasons why long-term investors should 'subscribe' to Syngene IPOSyngene is well positioned to capitalize on the advantages of its flexible business models that customize to their clients’ requirements gl...
- Syngene valuation justified by high growth prospectsPremium valuation seems justified given the good track record in performance, high quality of earnings and growth potential.
- Biocon Q3 Net dips 13% to Rs 91 crore; to offload 10-15% in SyngeneBio-pharmaceuticals contributed Rs 541 crore and research services Rs 220 crore to revenue for the reporting quarter.
Load More
